CATHETER PRECISION INC (VTAK)
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
$0.21+6.82%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Primary pillar broken — Gross profit improves to at least $390,000 in Q1 2026: Q2 2026 gross profit $97.8k vs trip <$132k.
Revenue grew 200% year-over-year to $432,000 in Q1 2026. Gross profit rose from $132,000 to $390,000 in the same quarter. The company is working on capital allocation through private placements. These show progress in growth and profit.
The company is still losing money with negative free cash flow. Revenue is small and uncertain. Capital raises may dilute shareholders and signal trouble.
The price is about 49% below our fair value near $1. Analysts expect revenue to double this year. Our view aligns with this but sees high risk.
Breaks if: No capital raises or funding events for 12 months
Breaks if: Gross profit falls below $132,000 in any future quarter
Revenue falls below $143,000 in any future quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is a speculative growth play. VTAK is currently navigating a challenging environment with high risks and a volatile management track record, but it has demonstrated strong revenue growth recently.
The market appears to be pricing in a justified valuation, with VTAK considered cheap compared to its peers. However, there is an expectations gap, indicating that the market may have low confidence in future earnings improvements.
Management is focused on increasing revenue and improving gross profit, with recent results showing strong revenue growth. However, there is a high probability of an earnings miss in the near term, which could impact investor sentiment.
The long-term thesis hinges on management's ability to sustain revenue growth and improve capital efficiency. Additionally, external factors such as sector performance and economic conditions will play a crucial role in shaping VTAK's future.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The company faces challenges as revenue growth remains insufficient. Recent earnings showed a beat, but revenue fell short of estimates, raising concerns.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, VTAK is in a watch state with mixed signals, reflecting both opportunities and risks. Not investment advice.